Vantage logo

Lilly spends big on mirikizumab

With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.

Vantage logo

Zogenix hands GW a win

A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.